BMS’ neuro renaissance was built on back of Celgene mega-merger

{
  "signal_id": "308ed0ef-b81f-ebb0-9b13-93275d4d7c07",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-31T05:04:48+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://www.biospace.com/drug-development/bms-neuro-renaissance-was-built-on-back-of-celgene-mega-merger",
    "title": "BMS’ neuro renaissance was built on back of Celgene mega-merger - BioSpace",
    "excerpt": "When it comes to neuroscience, Bristol Myers Squibb watchers are laser-focused on the upcoming readouts for Cobenfy - the schizophrenia drug the pharma acquired in the $14 billion purchase of Karuna Therapeutics - in Alzheimer’s disease psychosis. But BMS has a deeper neuro pipeline, built upon a much larger transaction - the $74 billion mega-merger with Celgene in 2019. Readouts for Cobenfy - approved in 2024 as the first new schizophrenia treatment in decades - in Alzheimer’s disease psychosis have been repeatedly delayed by clinical trial challenges and are now expected in 2027 , with a possible interim analysis later this year. But BMS touts a growing pipeline of neuroscience assets in Alzheimer’s, multiple sclerosis and other neuropsychiatric diseases. BMS stepped away from neuro in 2013, instead throwing its primary capital and resources behind immuno-oncology and other priority focuses. Ken Rhodes, vice president of neuroscience, told BioSpace he joined BMS in July 2023 “out of excitement about what the company was doing as it re-entered [the space].” The company’s neuroscience renaissance began with its $74 billion mega-merger with Celgene in 2019, Rhodes continued. “Through the acquisition and looking at the portfolio that the Celgene crew had put together, I think BMS realized the value in that portfolio and chose to sort of re-enter the therapeutic area in earnest.”...",
    "product": "Cobenfy",
    "summary": "Bristol Myers Squibb is currently evaluating its drug Cobenfy in clinical trials for bipolar-1 mania, Alzheimer’s disease agitation, Alzheimer’s cognition and pediatric autism irritability.",
    "planning": true,
    "image_url": "https://static.biospace.com/dims4/default/36e085e/2147483647/strip/true/crop/780x439+7+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F59%2Fbf%2F60da967548e9a801332254b00fae%2Fhope.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Cobenfy",
      "full_text": "Cobenfy",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-31T05:04:48Z",
    "article_sentence": "BMS is currently evaluating Cobenfy in bipolar-1 mania, Alzheimer’s disease agitation, Alzheimer’s cognition and pediatric autism irritability."
  }
}

curl https://signals.autobound.ai/v1/signals/308ed0ef-b81f-ebb0-9b13-93275d4d7c07 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'